FOXO4-DRI

FOXO4-DRI is a synthetic senolytic peptide designed to clear “zombie” senescent cells by breaking the FOXO4–p53 partnership inside them. In aged mice it restored fur, stamina and kidney function, but FOXO4-DRI has never been tested in a human trial. It is not FDA-approved and sells only as a research chemical.

What is FOXO4-DRI?

FOXO4-DRI is a lab-made peptide built for a single job: killing senescent cells, the worn-out “zombie” cells that stop dividing but refuse to die and instead leak inflammatory signals into aging tissue. The name is a spec sheet — “FOXO4” is the protein it targets, and “DRI” stands for D-retro-inverso, an engineering trick that rebuilds the peptide from mirror-image (D) amino acids in reverse order so it resists being chewed up by the body’s enzymes. FOXO4-DRI came out of Peter de Keizer’s lab and hit the scientific radar with a single 2017 paper. It is not a medicine you can be prescribed and not a supplement you can legally buy — in the United States, FOXO4-DRI exists only as a research chemical.

How does FOXO4-DRI work?

FOXO4-DRI works by acting as a molecular crowbar between two proteins. Senescent cells stay alive by having FOXO4 hold the “self-destruct” protein p53 in check; FOXO4-DRI is a decoy that jams into FOXO4, releasing p53 so it leaves the nucleus and the zombie cell triggers its own death (apoptosis) (Baar et al., 2017). Picture a bouncer (FOXO4) keeping a troublemaker (p53) away from the alarm switch — FOXO4-DRI pulls the bouncer aside so the alarm finally goes off, but mostly only in cells that were already leaning on that bouncer to survive. That selectivity for senescent over healthy cells is the whole pitch. The honest caveat: this mechanism is mapped in mice and in human cells in a dish, and how cleanly it plays out in a living human body is unconfirmed.

What does the research show?

FOXO4-DRI’s evidence is animal-only, and it has never been studied in a human — a promising rodent lead, not a proven therapy. The foundation is the 2017 Cell study: in naturally aged mice, FOXO4-DRI cleared senescent cells and restored fur density, running and grip endurance, and kidney function, and in a separate arm it blunted the toxicity of the chemotherapy drug doxorubicin (Baar et al., 2017). Later work moved into human tissue in a dish — a 2021 study showed FOXO4-DRI selectively wiped out senescent human cartilage cells while sparing younger ones, though the surviving cells didn’t regain full cartilage-building ability (Huang et al., 2021).

Here is the part that matters most, and it’s easy to miss: a PubMed search for FOXO4-DRI returns records tagged “human,” but those are experiments on human cells in culture — not human trials. ClinicalTrials.gov lists zero registered FOXO4-DRI studies. So the encouraging mouse data and the cell-culture work are the whole file; the human-efficacy chapter of FOXO4-DRI hasn’t been written yet.

What the community reports

FOXO4-DRI has a following in longevity and biohacking circles, where the 2017 mouse results — restored fur, better stamina, healthier kidneys — get retold as if the same rejuvenation is on the table for people. Reported use centers on short injectable courses aimed at “clearing senescent cells.” These accounts are anecdotal: they are not controlled data, there is no way to confirm anyone actually reduced their senescent-cell burden, and they carry heavy survivorship bias, since people who feel nothing rarely post. FOXO4-DRI community reports are useful for understanding the excitement, not for proving the peptide does anything in a human.

Is FOXO4-DRI safe? Side effects

FOXO4-DRI’s honest safety answer is “unknown in humans.” There is no clinical trial, no human safety dataset, and no long-term follow-up of any kind. The theoretical concern is baked into how FOXO4-DRI works: it deliberately drives cells to self-destruct through the p53 pathway, and doing that throughout the body is a powerful intervention whose off-target effects in a person simply haven’t been measured. On top of the biology, the practical risk is the product itself — FOXO4-DRI is sold as an unregulated research chemical, so its purity, dose accuracy, and sterility are entirely at the mercy of the lab that mixed it. Anyone reading a “well tolerated in mice” line should remember that mice are not people and a handful of rodent studies is not a safety record.

FDA & legal status (2026)

FOXO4-DRI is not FDA-approved for any use, and it is not a legal dietary supplement. As of 2026, openFDA lists no approved FOXO4-DRI products, and in the United States FOXO4-DRI is sold strictly as a research chemical “for research use only.” No registered clinical trial exists, so there is no pending approval to track — the senolytic field as a whole is moving, but FOXO4-DRI specifically has no regulatory timeline yet. Treat any status claim as dated and re-check it; the dated breakdown sits in the regulatory-status block above.

How is FOXO4-DRI used, and can it be mixed?

FOXO4-DRI is supplied as a lyophilized (freeze-dried) powder that has to be reconstituted with bacteriostatic water before use, and there is no validated human dose — the mouse studies used repeated injections over a few weeks, and no human protocol has been established, so any community dosing is unvalidated guesswork rather than a tested regimen. The arithmetic of turning a vial into a per-injection amount is still just arithmetic — our reconstitution & dosing calculator handles the “X mg vial, Y mL water, Z target” math. People also ask whether FOXO4-DRI can share a syringe with other peptides; our mixing compatibility reference covers what is commonly combined and, more often, where the honest answer is “no data.”

FOXO4-DRI vs other longevity peptides

FOXO4-DRI is one of several peptides that get filed under “longevity,” but it targets something specific that the others don’t. FOXO4-DRI is a senolytic — it tries to remove zombie cells outright — whereas epitalon is pursued for telomere and circadian effects and MOTS-c is a mitochondrial peptide studied for metabolism and exercise capacity. None of the three has human RCT proof for an anti-aging claim, and each sits at a different rung of the evidence ladder. You can see the whole family on the longevity peptides hub.

Hype vs reality

The biggest FOXO4-DRI claim floating around is that it “reverses aging,” lifted straight from the 2017 mouse headlines. The reality: FOXO4-DRI reversed specific markers of aging in mice — fur, stamina, kidney function — and cleared senescent human cells in a dish. That is a proof of concept for the senolytic idea, and it’s why the peptide is worth watching. It is also animal-only with no human study of any kind, which means “reverses aging in people” is a hope, not a result. Both things are true at once, and FOXO4-DRI is a good example of why the gap between them matters.

Frequently asked questions

Is FOXO4-DRI proven to work in humans?

No. FOXO4-DRI has never been tested in a human trial — ClinicalTrials.gov lists zero studies. The evidence is strong-looking mouse data plus experiments on human cells in culture. That makes FOXO4-DRI a promising senolytic lead, not a proven human therapy, and we grade it animal-only until a human study reports.

Is FOXO4-DRI a senolytic?

Yes. FOXO4-DRI is one of the first designed senolytic peptides — its entire purpose is selectively killing senescent (“zombie”) cells by disrupting the FOXO4–p53 interaction so p53 leaves the nucleus and the cell self-destructs. That selective clearance is what the mouse and human-cell studies measured.

Is FOXO4-DRI legal?

FOXO4-DRI is legal to buy and sell in the United States as a research chemical, but it is not an approved drug and not a legal dietary supplement, and it cannot be sold for human consumption. This is why every vendor labels FOXO4-DRI “for research use only.”

Is FOXO4-DRI banned in sport?

Effectively yes. Because FOXO4-DRI has no regulatory approval for human use, it falls under WADA’s S0 “non-approved substances” category, which prohibits such compounds at all times for athletes under anti-doping rules.

How is FOXO4-DRI taken?

In the research literature FOXO4-DRI was injected, and there is no established human route or dose. Any regimen you see described online is anecdotal and unvalidated — FOXO4-DRI has not been dosed in a human trial, so a “protocol” for it is guesswork, not tested science.

Who is FOXO4-DRI for — and who should be cautious?

FOXO4-DRI draws in the longevity-curious — people who read that a peptide made old mice young-ish and want to understand whether it could do anything for a human. The honest framing: the senolytic concept behind FOXO4-DRI is one of the more compelling ideas in aging research, and the 2017 mouse data earned the attention. But FOXO4-DRI has zero human studies, no safety record in people, no validated dose, and a mechanism — pushing cells to self-destruct body-wide — that deserves real trials before anyone counts on it. Anyone with a cancer history, anyone pregnant, and anyone unwilling to be an uncontrolled experiment has every reason to wait for the science to catch up to the excitement.